The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

LI.ak

Cardiotoxicity

Publications

Kobat H, Elkonaissi I, Foreman E, O'Brien M, Dorak MT, Nabhani-Gebara S

Investigating the efficacy of osimertinib and crizotinib in phase 3 clinical trials on anti-cancer treatment-induced cardiotoxicity: are real-world studies the way forward?

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2022 Feb 15;;10781552221077417 — 2022 Feb 15 — 10781552221077417

Tartarone A, Gallucci G, Lazzari C, Lerose R, Lombardi L, Aieta M

Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management.

Future oncology (London, England) 2015;11;2043-8 — 2015 — 2043-8